Halozyme Therapeutics, Inc.
11388 Sorrento Valley Road
San Diego,
CA 92121
United States - Map
Phone: 858-794-8889
Fax: 858-704-8311
Web Site: http://www.halozyme.com
| Halozyme Therapeutics, Inc., a biopharmaceutical company, develops and commercializes products targeting the extracellular matrix for the endocrinology, oncology, dermatology, and drug delivery markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes, known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozymes Enhanze Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has partnerships with Roche to apply Enhanze Technology to Roches biological therapeutics for up to 13 targets; and with Baxter BioScience to apply Enhanze Technology to Baxters biological therapeutic compound, GAMMAGARD LIQUID. The product candidates in Halozymes research pipeline target multiple areas of significant unmet medical need. The company was founded in 1998 and is based in San Diego, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Jonathan Lim M.D, 37
Chief Exec. Officer, Pres and Exec. Director |
$
375.00K |
$
1.30M | Dr. Gregory I. Frost Ph.D., 37
Co-Founder, Chief Scientific Officer, VP |
$
323.00K |
$
3.60M | Mr. William J. Fallon , 52
VP of Manufacturing and Operations |
$
270.00K |
$
0 | Mr. Robert L. Little , 59
Chief Commercial Officer and VP |
$
322.00K |
$
0 | Mr. David A. Ramsay MBA, 44
VP of Corp. Devel. and Sec. |
$
260.00K |
$
0 |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.51% Nasdaq 
Profile
